Rhinostop Extra, spray 0.05% 15 ml

Pharmacodynamics

Oxymetazoline belongs to the group of local vasoconstrictors (decongestants) with alpha-adrenomimetic action, causes narrowing of blood vessels of nasal mucosa, thus eliminating edema and hyperemia of nasopharyngeal mucosa.

When applied topically to the inflamed nasal cavity mucosa, it reduces its swelling and associated mucus hypersecretion (nasal discharge) which facilitates nasal passageways drainage. It restores nasal breathing.

The elimination of nasal cavity mucous membrane edema helps restore aeration of the sinus cavity, middle ear cavity, which reduces the likelihood of bacterial complications (maxillary sinusitis, sinusitis, otitis media).

In local intranasal application in therapeutic concentrations it does not irritate and does not cause nasal mucous membrane hyperemia.

The drug takes effect quickly, within a few minutes. The duration of action of the drug is up to 12 hours.

Pharmacokinetics

In local intranasal administration, oxymetazoline has no systemic action. The elimination half-life of oxymetazoline when administered intranasally is 35 hours. 2.1% of oxymetazoline is excreted with urine and about 1.1% with feces.

Indications

Treatment of acute respiratory diseases accompanied by a runny nose;

allergic rhinitis;

vasomotor rhinitis;

to restore drainage in case of inflammation of the paranasal sinuses, eustachitis, otitis media;

to eliminate swelling before diagnostic manipulations in the nasal passages.

Pharmacological effect

Pharmacodynamics

Oxymetazoline belongs to the group of local vasoconstrictors (decongestants) with an alpha-adrenomimetic effect, causing constriction of the blood vessels of the nasal mucosa, thus eliminating swelling and hyperemia of the nasopharyngeal mucosa.

When applied topically to the inflamed mucous membrane of the nasal cavity, it reduces its swelling and concomitant hypersecretion of mucus (nasal discharge), which facilitates the drainage of the nasal passages. Restores nasal breathing.

Elimination of swelling of the nasal mucosa helps restore aeration of the paranasal sinuses and middle ear cavity, which reduces the likelihood of bacterial complications (sinusitis, sinusitis, otitis media).

When used locally intranasally in therapeutic concentrations, it does not irritate or cause hyperemia of the nasal mucosa.

The drug begins to act quickly, within a few minutes. The duration of action of the drug is up to 12 hours.

Pharmacokinetics

When administered locally intranasally, oxymetazoline does not have a systemic effect. The half-life of oxymetazoline when administered intranasally is 35 hours. 2.1% of oxymetazoline is excreted in the urine and about 1.1% in the feces.

Special instructions

Avoid getting the drug into your eyes.

Long-term use and overdose of the drug should be avoided, especially in children.

To avoid the spread of infection, it is necessary to use the drug individually.

Impact on the ability to drive vehicles and machinery

After a long
use of cold remedies containing oxymetazoline in doses exceeding
recommended, a general effect on the cardiovascular system and
central nervous system. In these cases, care should be taken when
driving vehicles and engaging in other potentially dangerous activities
activities that require increased concentration and speed
psychomotor reactions.

Active ingredient

Oxymetazoline

Composition

Active ingredient:

Oxymetazoline hydrochloride – 0.5 mg.

Excipients:
Citric acid monohydrate – 0.609 mg;
sodium citrate dihydrate – 3.823 mg;
glycerol – 24.348 mg;
benzalkonium chloride – 0.15 mg;
purified water – up to 1 ml.

Pregnancy

When used during pregnancy or breastfeeding, do not exceed the recommended dose. The drug can only be used in cases where the potential benefit to the mother outweighs the potential risk to the fetus or child.

Before using the drug if you are pregnant
or think you might be pregnant, or are planning
pregnancy, you should consult your doctor.

Contraindications

Hypersensitivity to the components of the drug;

atrophic (dry) rhinitis;

angle-closure glaucoma;

condition after transsphenoidal hypophysectomy;

surgical interventions on the dura mater (history);

children under 6 years of age.

With caution

With increased intraocular pressure, chronic heart failure, arterial hypertension, angina pectoris; arrhythmias; chronic renal failure; in patients with prostatic hyperplasia with clinical symptoms (urinary retention); severe atherosclerosis; with hyperthyroidism; diabetes mellitus; pheochromocytoma; tachycardia; therapy with monoamine oxidase inhibitors (MAOIs) (including for up to 14 days after their discontinuation) and tricyclic antidepressants, as well as other drugs that increase blood pressure; porphyria; pregnancy, during breastfeeding.

Side Effects

Uncommon: burning or dryness of the mucous membranes of the nasal cavity, sneezing, nosebleeds.

In rare cases: after the effect of the drug wears off, a feeling of “stuffiness” in the nose (reactive hyperemia).

Frequency unknown: dryness of the mucous membranes of the mouth and throat, increased volume of secretions released from the nose.

Side effects caused by the systemic action of the drug:

Uncommon: Quincke’s edema, itching.

Rarely: increased blood pressure, headache, dizziness, palpitations, tachycardia, anxiety, irritability, sleep disturbance (in children), nausea, insomnia, exanthema, blurred vision (if it gets into the eyes).

Very rare: restlessness, fatigue, drowsiness, sedation, hallucinations, convulsions, respiratory arrest (in infants).

Long-term continuous use of vasoconstrictor drugs can lead to tachyphylaxis, atrophy of the nasal mucosa and recurrent swelling of the nasal mucosa (rhinitis medicamentosa).

If any of the side effects indicated in the instructions
effects get worse or you notice any other side effects that are not
specified in the instructions, inform your doctor.

Interaction

The drug slows down the absorption of local anesthetic drugs and prolongs their effect.

When used concomitantly with monoamine oxidase inhibitors (during the previous 2 weeks and within 2 weeks after their discontinuation), tricyclic antidepressants or other drugs that increase blood pressure, an increase in blood pressure may occur.

Joint appointment
other vasoconstrictor drugs increases the risk of side effects.

Overdose

Clinical signs of intoxication with imidazole derivatives can be nonspecific and unclear, since phases of hyperactivity are replaced by phases of depression of the central nervous system, cardiovascular and respiratory systems.

Symptoms: anxiety, restlessness, hallucinations, convulsions, decreased body temperature, lethargy, drowsiness, coma, constriction or dilation of pupils, fever, sweating, pallor, cyanosis, palpitations, bradycardia, arrhythmia, cardiac arrest, increased blood pressure, decreased blood pressure, nausea, vomiting, respiratory depression, respiratory arrest.

In children, an overdose can cause the development of symptoms from the central nervous system, such as: agitation, convulsions, coma, bradycardia, respiratory arrest, as well as an increase in blood pressure with a subsequent possible decrease in blood pressure.

Treatment: gastric lavage, taking activated carbon (in case of accidental ingestion of the drug); symptomatic.

For severe
In cases of overdose, intensive therapy in a hospital setting is indicated. Application
Vasoconstrictors are contraindicated.

Storage conditions

Store at a temperature not exceeding 25 °C.

Shelf life

2 years.

Manufacturer

Pharmstandard-Leksredstva, Russia